Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Estudio de AZD9833 y un inhibidor de CDK4/6 en pacientes con cáncer de ...
A trial of AZD9833 for breast cancer (SERENA-4) | Cancer Research UK
阿斯利康乳腺癌新药 AZD9833 国内获批临床 2 月 20 日，CDE 官网显示， 阿斯利康 的雌激素受体拮抗剂 AZD9833 首次在 ...
Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 ...
Discovery of AZD9833, a potent and orally bioavailable selective ...
Camizestrant (AZD9833) | ≥99%(HPLC) | Selleck | エストロゲン/プロゲストゲン受容体 化学物質
阿斯利康口服SERD乳腺癌II期研究成功 10月26日， 阿斯利康 宣布，其下一代口服选择性雌激素受体降解剂（SERD ...
The Next-Generation Oral Selective Estrogen Receptor Degrader ...
Chemspace | Analogs to New Biological Tool Compounds | Camizestrant ...
AZD-9833 is an Orally Active Estrogen Receptor (ER) Antagonist ...
Addition of Fluorine and a Late-Stage Functionalization (LSF) of the ...
AZD-9833 (Camizestrant); Estrogen receptor antagonist 2 - 小分子，大梦想
Camizestrant, AZD 9833 « New Drug Approvals
新药研发：阿斯利康临床I期ER降解剂&拮抗剂AZD9833的发现|阿斯利康|降解剂|拮抗剂|化合物|乳腺癌|细胞株|-健康界
camizestrant (AZD9833) / AstraZeneca
Study on the Effects and Safety of Camizestrant (AZD9833) Compared to ...
ACS Medicinal Chemistry Letters | Vol 11, No 12
ISSX 2022 - Hypha Discovery
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast ...
Strategies toward Discovery of Potent and Orally Bioavailable ...
Abstract 5674: Discovery of AZD9833, an oral small molecule selective ...
Abstract P3-07-13: The next generation oral selective estrogen receptor ...
Discovery of novel covalent selective estrogen receptor degraders ...
Frontiers | Next generation selective estrogen receptor degraders in ...
Targeting Breast Cancer: An Overlook on Current Strategies
Abstract PO3-19-09: SERENA-1: Results from a Phase 1 study (Parts I/J ...
Frontiers | Optimization of small molecule degraders and antagonists ...
Selective Estrogen Receptor Degrader/Modulator RAD1901 | Semantic Scholar
Camizestrant (AZD-9833) | Estrogen Receptor Antagonist | MedChemExpress
Illustration of the drug camizestrant (AZD9833). Camizestrant is an ...
Camizestrant (AZD-9833) | CAS 2222844-89-3 | AbMole BioScience ...
(A) Backbone root-mean-square deviations of the protein in the 100 ns ...
Camizestrant TFA | Estrogen Receptor/ERR | TargetMol
阿斯利康第二代PARP1抑制剂AZD5305联合AZD9833治疗BRCA或PALB2突变的晚期乳腺癌患者 - 知乎
tilatamig samrotecan (AZD9592) / AstraZeneca
SERDs in HR+HER2- Breast Cancer | PDF
Ten Ways Degraders Differentiate from Traditional Small Molecules
Chemical structures of marketed and investigational SERM/SERDs. SERD ...
CAMBRIA-2: An Adjuvant Endocrine-based Therapy Study of Camizestrant ...
Buy Other Targets | Life Sciences - Ligands Products | Biosynth
A phase I study of RAD1901, an oral selective estrogen receptor ...
First-line systemic treatment with palbociclib in women aged ≥70 years ...
Camizestrant (AZD-9833) | CAS#2222844-89-3 MCE貨號HY-136255
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC ...
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of ...
Oxidized Metabolites and Unusual Conjugates of AZD9496 - Hypha Discovery
Global Targeted Protein Degraders 2025 - Preview Copy.pdf
AstraZeneca Leading Revolution in Precision Oncology Therapy: The ...
氟维司群回归医保，CSCO乳腺癌指南I级推荐！
Camizestrant: A Next-Generation Oral SERD for HR-Positive, HER2 ...
AD9833 undocumented parts of the datasheet - Q&A - Direct Digital ...
ER inhibition by ER antagonist, PROTAC, and MGDs. Target proteins ...
临床在研的 BRD4 抑制剂怎么样？ - 知乎
Structure d’un ARNt et complémentarité codon-anticodon | Planet-Vie
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance ...
Chemical structures of AZD3409. Reaction I: AZD3409 is broken down by ...
Mechanism of action of Orserdu as SERM and SERD | Download Scientific ...
AstraZeneca demonstrated the significant findings from the SERENA...
